{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:20:51Z","timestamp":1760646051841},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T00:00:00Z","timestamp":1368489600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Altern Med"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Diabetes remains a major health problem worldwide. Low-risk low-cost alternatives to pharmaceutical interventions are needed where lifestyle modifications have failed. We conducted a double-blind randomised placebo controlled trial to investigate the efficacy of a Chinese herbal formula, <jats:italic>Jiangtang Xiaozhi<\/jats:italic>, in treating impaired glucose control and insulin resistance in persons with prediabetes and controlled diabetes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Seventy-one patients with prediabetes or \u2018controlled\u2019 diabetes were randomised to receive 3 capsules of <jats:italic>Jiangtang Xiaozhi<\/jats:italic> (n = 39) or placebo (n = 32) three times daily for 16\u00a0weeks with a follow up eight weeks later (week 24). The primary outcome was change in glycaemic control as evidenced by fasting blood glucose (FBG), post-prandial plasma glucose and glycosylated haemoglobin (HbA1c). Other measures included change in fasting insulin, insulin resistance and sensitivity, lipids, C-reactive protein (CRP), body mass index (BMI), waist girth, blood pressure (BP), health related quality of life (HRQoL) and safety. Analysis of covariance (ANCOVA) was used to model outcomes at 16\u00a0weeks, by treatment group corrected for baseline level of the outcome variable.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In patients receiving <jats:italic>Jiangtang Xiaozhi<\/jats:italic>, FBG was not significantly different (p = 0.73) compared to placebo after 16\u00a0weeks of treatment (6.3 \u00b1 1.1\u00a0mmol\/L vs 6.7 \u00b1 1.3\u00a0mmol\/L). There was a significant difference (p = 0.04) in the mean levels of fasting insulin between the treatment group (11.6 \u00b1 5.5\u00a0mmol\/L) and the placebo group (22.1 \u00b1 25.9\u00a0mmol\/L). Insulin resistance slightly decreased in the treatment group (1.58 \u00b1 0.74) compared to that of the placebo group (2.43 \u00b1 1.59) but this change did not reach statistical significance (p = 0.06). Patients taking <jats:italic>Jiangtang Xiaozhi<\/jats:italic> had a significant improvement in high-density lipoprotein (HDL) level compared to the placebo group at week 16 (p = 0.03). Mean levels of cholesterol, triglycerides, BMI, waist-girth, HRQoL, BP, CRP and insulin sensitivity were not significantly different between the two groups. The herbal medicine was well tolerated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In the current study, the 16\u00a0week <jats:italic>Jiangtang Xiaozhi<\/jats:italic> treatment did not lower fasting blood glucose, but it improved serum insulin and HDL cholesterol in a Western population with prediabetes or controlled diabetes. Our trial may have been underpowered. Dosage needs to be considered before commencing a longer adequately powered trial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Australian New Zealand Clinical Trials Registry ACTRN12612000128897;<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=362005\" ext-link-type=\"uri\">https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=362005<\/jats:ext-link>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1472-6882-13-104","type":"journal-article","created":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T16:17:51Z","timestamp":1368548271000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Chinese herbal medicine for impaired glucose tolerance: a randomized placebo controlled trial"],"prefix":"10.1186","volume":"13","author":[{"given":"Suzanne J","family":"Grant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis Hsu-Tung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hosen","family":"Kiat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Bensoussan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,14]]},"reference":[{"key":"1352_CR1","volume-title":"IDFDiabetes Atlas","author":"International Diabetes Federation","year":"2007","unstructured":"International Diabetes Federation: IDFDiabetes Atlas. 2007, Brussels, Belgium: International Diabetes Federation,http:\/\/www.idf.org\/diabetesatlas, 3,","edition":"3"},{"key":"1352_CR2","volume-title":"Diabetologia","author":"E Barr","year":"2009","unstructured":"Barr E, Cameron A, Balkau B, Zimmet P, Welborn T, Tonkin A, Shaw J: HOMA insulin sensitivity index and the risk of all-cause mortality and cardiovascular disease events in the general population: the australian diabetes, obesity and lifestyle study (AusDiab) study. Diabetologia. 2009, 10.1007\/s00125-009-1588-0."},{"issue":"2","key":"1352_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2337\/diacare.22.2.233","volume":"22","author":"M Coutinho","year":"1999","unstructured":"Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999, 22 (2): 233-240. 10.2337\/diacare.22.2.233.","journal-title":"Diabetes Care"},{"issue":"11","key":"1352_CR4","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2337\/diacare.24.11.1855","volume":"24","author":"HC Gerstein","year":"2001","unstructured":"Gerstein HC: Fasting versus postload glucose levels. Diabetes Care. 2001, 24 (11): 1855-1857. 10.2337\/diacare.24.11.1855.","journal-title":"Diabetes Care"},{"issue":"23","key":"1352_CR5","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006, 355 (23): 2427-2443. 10.1056\/NEJMoa066224.","journal-title":"N Engl J Med"},{"issue":"2","key":"1352_CR6","doi-asserted-by":"publisher","first-page":"324","DOI":"10.2337\/diacare.25.2.324","volume":"25","author":"LE Egede","year":"2002","unstructured":"Egede LE, Ye X, Zheng D, Silverstein MD: The prevalence and pattern of complementary and alternative medicine use in individuals with diabetes. Diabetes Care. 2002, 25 (2): 324-329. 10.2337\/diacare.25.2.324.","journal-title":"Diabetes Care"},{"key":"1352_CR7","doi-asserted-by":"crossref","unstructured":"Grant SJ, Chang D, Kiat H, Klupp NL, Liu JP, Li X: Chinese herbal medicines for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev. 2009, CD006690-10.1002\/14651858. CD006690.pub2, 4","DOI":"10.1002\/14651858.CD006690.pub2"},{"issue":"1","key":"1352_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/ijerph8010015","volume":"8","author":"J Efird","year":"2011","unstructured":"Efird J: Blocked randomization with randomly selected block sizes. Int J Environ Res Public Health. 2011, 8 (1): 15-20.","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"1352_CR9","first-page":"910","volume":"32","author":"Z Chen","year":"2012","unstructured":"Chen Z, Xia C, Wei Z: Clinical study of Jiangtang Xiaozhi capsule in treating type 2 diabetes mellitus patients. Chin J Integr Tradit Chin Med. 2012, 32 (7): 910-913.","journal-title":"Chin J Integr Tradit Chin Med"},{"issue":"16","key":"1352_CR10","first-page":"143","volume":"16","author":"Z Ge","year":"2010","unstructured":"Ge Z, Jin L, Yan A, Dong X, Liu J, Liu J: Study of Jiangtang Xiaozhi on decreasing blood glucose in rat and mouse models of diabetes mellitus. Chin J Exp Tradit Med Formulae. 2010, 16 (16): 143-416.","journal-title":"Chin J Exp Tradit Med Formulae"},{"issue":"9","key":"1352_CR11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5694\/j.1326-5377.2007.tb00998.x","volume":"186","author":"SMKM Twigg","year":"2007","unstructured":"Twigg SMKM, Davis TM, Neylon EK, Flack JR: Prediabetes: a position statement from the australian diabetes society and australian diabetes educators association. Med J Australia. 2007, 186 (9): 461-465.","journal-title":"Med J Australia"},{"issue":"14","key":"1352_CR12","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1001\/jama.295.14.1688","volume":"295","author":"CD Saudek","year":"2006","unstructured":"Saudek CD, Derr RL, Kalyani RR: Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA. 2006, 295 (14): 1688-1697. 10.1001\/jama.295.14.1688.","journal-title":"JAMA"},{"key":"1352_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0895-4356(00)00314-0","volume":"54","author":"R Bender","year":"2001","unstructured":"Bender R, Lange S: Adjusting for multiple testing \u2013 when and how?. J Clin Epidemiol. 2001, 54: 343-349. 10.1016\/S0895-4356(00)00314-0.","journal-title":"J Clin Epidemiol"},{"key":"1352_CR14","volume-title":"How to score version 2 of the SF-36 health survey","author":"JE Ware","year":"2000","unstructured":"Ware JE, Kosinski M, Dewey JE: How to score version 2 of the SF-36 health survey. 2000, Lincoln: Quality Metric Inc"},{"issue":"12","key":"1352_CR15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.2337\/diacare.21.12.2191","volume":"21","author":"JC Levy","year":"1998","unstructured":"Levy JC, Matthews DR, Hermans MP: Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998, 21 (12): 2191-2192. 10.2337\/diacare.21.12.2191.","journal-title":"Diabetes Care"},{"issue":"5","key":"1352_CR16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.2337\/diacare.22.5.818","volume":"22","author":"M Emoto","year":"1999","unstructured":"Emoto M, Nishizawa Y, Maekawa K, Yoshikazu H: Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care. 1999, 22 (5): 818-822. 10.2337\/diacare.22.5.818.","journal-title":"Diabetes Care"},{"issue":"6","key":"1352_CR17","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","volume":"27","author":"TMLJC Wallace","year":"2004","unstructured":"Wallace TMLJC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care. 2004, 27 (6): 1487-1495. 10.2337\/diacare.27.6.1487.","journal-title":"Diabetes Care"},{"issue":"4","key":"1352_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s11136-006-9154-4","volume":"16","author":"G Hawthorne","year":"2007","unstructured":"Hawthorne G, Osborne R, Taylor A, Sansoni J: The SF36 Version 2: critical analyses of population weights, scoring algorithms and population norms. Qual Life Res. 2007, 16 (4): 661-673. 10.1007\/s11136-006-9154-4.","journal-title":"Qual Life Res"},{"key":"1352_CR19","volume-title":"Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose. Evidence Report\/Technology Assessment No. 128. (Prepared by the McMaster University Evidence-based Practice Center under Contract No. 290-02-0020). AHRQ Pub. No","author":"PL Santaguida","year":"2005","unstructured":"Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, Booker L, Yazdi H: Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose. Evidence Report\/Technology Assessment No. 128. (Prepared by the McMaster University Evidence-based Practice Center under Contract No. 290-02-0020). AHRQ Pub. No 05-E026-2. 2005, Rockville, MD: Agency for Healthcare Research and Quality"},{"issue":"1","key":"1352_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s005920050098","volume":"35","author":"S Fischer","year":"1998","unstructured":"Fischer S, Hanefeld M, Spengler M, Boehme K, Temelkova-Kurktschiev T: European study on dose\u2013response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol. 1998, 35 (1): 34-40. 10.1007\/s005920050098.","journal-title":"Acta Diabetol"},{"issue":"3","key":"1352_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2337\/diabetes.52.3.581","volume":"52","author":"RP Robertson","year":"2003","unstructured":"Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H: Glucose toxicity in \u03b2-cells: type 2 diabetes, good radicals gone Bad, and the glutathione connection. Diabetes. 2003, 52 (3): 581-587. 10.2337\/diabetes.52.3.581.","journal-title":"Diabetes"},{"issue":"6","key":"1352_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1046\/j.1463-1326.2003.00302.x","volume":"5","author":"B Ramachandran","year":"2003","unstructured":"Ramachandran B, Kandaswamy M, Narayanan V, Subramanian S: Insulin mimetic effects of macrocyclic binuclear oxovanadium complexes on streptozotocin-induced experimental diabetes in rats. Diabetes Obes Metab. 2003, 5 (6): 455-461. 10.1046\/j.1463-1326.2003.00302.x.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"1352_CR23","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.2337\/dc09-0676","volume":"32","author":"C Snehalatha","year":"2009","unstructured":"Snehalatha C, Mary S, Selvam S, Sathish Kumar CK, Shetty SBA, Nanditha A, Ramachandran A: Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the indian diabetes prevention programme-1 (IDPP-1). Diabetes Care. 2009, 32 (10): 1796-1801. 10.2337\/dc09-0676.","journal-title":"Diabetes Care"},{"issue":"7","key":"1352_CR24","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1210\/jc.2007-2404","volume":"93","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P: Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008, 93 (7): 2559-2565. 10.1210\/jc.2007-2404.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1352_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2337\/diabetes.54.1.166","volume":"54","author":"V Lyssenko","year":"2005","unstructured":"Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Niss\u00e9n M, Isomaa B, Forsen B, Homstr\u00f6m N, Saloranta C: Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes. 2005, 54 (1): 166-174. 10.2337\/diabetes.54.1.166.","journal-title":"Diabetes"},{"issue":"11","key":"1352_CR26","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","volume":"44","author":"UKPDS Group","year":"1995","unstructured":"UKPDS Group: U.K. Prospective diabetes study 16: overview of 6 years' therapy of type II diabetes, a progressive disease.(U.K. Prospective diabetes study group). Diabetes. 1995, 44 (11): 1249-1210","journal-title":"Diabetes"},{"issue":"6","key":"1352_CR27","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1172\/JCI7231","volume":"104","author":"CB Weyer","year":"1999","unstructured":"Weyer CB, Mott CDM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999, 104 (6): 787-794. 10.1172\/JCI7231.","journal-title":"J Clin Invest"},{"issue":"1","key":"1352_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2337\/dc09-1070","volume":"33","author":"S Sung KRGK","year":"2010","unstructured":"Sung KRGK S: Utility off homeostasis model assessment of [beta]-cell function in predicting diabetes in 12,924 healthy koreans. Diabetes Care. 2010, 33 (1): 200-202. 10.2337\/dc09-1070.","journal-title":"Diabetes Care"},{"issue":"10","key":"1352_CR29","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.2337\/diacare.19.10.1138","volume":"19","author":"SM Haffner","year":"1996","unstructured":"Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H: A prospective analysis of the HOMA model. The Mexico city diabetes study. Diabetes Care. 1996, 19 (10): 1138-1141. 10.2337\/diacare.19.10.1138.","journal-title":"Diabetes Care"},{"key":"1352_CR30","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.2337\/diab.44.12.1386","volume":"44","author":"SM Haffner","year":"1995","unstructured":"Haffner SM, Gaskill HSP: Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes. 1995, 44: 1386-1391. 10.2337\/diabetes.44.12.1386.","journal-title":"Diabetes"},{"issue":"4","key":"1352_CR31","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1053\/meta.2003.50078","volume":"52","author":"M Kanauchi","year":"2003","unstructured":"Kanauchi M, Nakajima M, Saito Y, Kanauchi K: Pancreatic beta-cell function and insulin sensitivity in japanese subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes mellitus. Metabolism. 2003, 52 (4): 476-481. 10.1053\/meta.2003.50078.","journal-title":"Metabolism"},{"issue":"4","key":"1352_CR32","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M","volume":"15","author":"J Levy","year":"1998","unstructured":"Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR: Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the belfast diet study. Diabet Med. 1998, 15 (4): 290-296. 10.1002\/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M.","journal-title":"Diabet Med"},{"issue":"10","key":"1352_CR33","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2165\/00003495-200262100-00004","volume":"62","author":"FMAC Martens","year":"2002","unstructured":"Martens FMAC, Visseren FLJ, Lemay J, de Koning EJP, Rabelink TJ: Metabolic and additional vascular effects of thiazolidinediones. Drugs. 2002, 62 (10): 1463-1480. 10.2165\/00003495-200262100-00004.","journal-title":"Drugs"},{"issue":"15","key":"1352_CR34","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1161\/01.CIR.0000091339.70120.53","volume":"108","author":"AMD Festa","year":"2003","unstructured":"Festa AMD, Hanley AJGP, Tracy RPP, D'Agostino RJP, Haffner SMMD: Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. [Report]. Circulation. 2003, 108 (15): 1822-1830. 10.1161\/01.CIR.0000091339.70120.53.","journal-title":"Circulation"},{"issue":"5","key":"1352_CR35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.297.5.499","volume":"297","author":"SJ Nicholls","year":"2007","unstructured":"Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL: Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007, 297 (5): 499-508. 10.1001\/jama.297.5.499.","journal-title":"JAMA"},{"issue":"4","key":"1352_CR36","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1210\/jc.2002-021786","volume":"88","author":"I Pavo","year":"2003","unstructured":"Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, Shestakova M, Herz M, Johns D, Schluchter BJ: Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab. 2003, 88 (4): 1637-1645. 10.1210\/jc.2002-021786.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1352_CR37","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"AJ Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001, 23 (8): 1296-1310. 10.1016\/S0149-2918(01)80109-0.","journal-title":"Clin Ther"}],"container-title":["BMC Complementary and Alternative Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6882-13-104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6882-13-104\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6882-13-104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6882-13-104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:42:32Z","timestamp":1630539752000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/1472-6882-13-104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,14]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1352"],"URL":"https:\/\/doi.org\/10.1186\/1472-6882-13-104","relation":{},"ISSN":["1472-6882"],"issn-type":[{"value":"1472-6882","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,14]]},"assertion":[{"value":"16 June 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"104"}}